Invitation

Scientific Programme

General Information

Accreditation

Teaching Faculty

Wed 19.03 – Fri 21.03.2025

City: London

Type of event: on site

Invitation

Dear Colleagues

It is a pleasure to announce the 2nd Postgraduate Course in Cardiometabolic Medicine, a timely and highly acclaimed educational programme conceived by Zurich Heart House – London Heart House, King’s College, and Royal Brompton & Harefield Hospitals, which will address an unmet educational need.

Cardiometabolic disorders represent a cluster of interrelated risk factors, primarily dyslipidemia, hypertension, elevated fasting blood glucose, obesity and non-alcoholic steatohepatitis. A combination of several of these risk factors massively increases the incidence and mortality of coronary heart disease and stroke. The strong association between metabolic disorders and cardiovascular health delivers a compelling reason to improve awareness of this cluster by identifying the risk factors and inducing targeted interventions.

The Postgraduate Course in Cardiometabolic Medicine consists of a three-day programme. State of the art lectures alternate with a great variety of interactive sessions, including workshops, rapid fire sessions and hands-on imaging sessions.

The course offers a unique opportunity to become an expert in the seminal area of cardiometabolic medicine. We are looking forward to receiving your application and meeting you in London.
Sincerely,

Andrew Krentz
Thomas F. Lüscher
Mahmoud Barbir
John E. Deanfield
Michael Papadakis
Naveed Sattar 

---

Scientific Programme

Tuesday, March 19^th, 2025 (UK time)

Venue: The Royal Society of Medicine

09:00 – 09:30 | REGISTRATION AND COFFEE
09:30 – 9:45 | Opening Session
09:30	Welcome by the course directors & Course concept and structure

09:45 – 11:30 | Session 1: Obesity I- Causes and mechanisms Chairs: Barbara McGowan & Michael Papadakis
09:45	Is obesity a disease? If so, how do we diagnose it? The ESC’s view	Konstantinos Koskinas, Berne
10:05	Obesity and inflammation	Fiona McGillicuddy, Dublin
10:25	What links adiposity to CVD?	Naveed Sattar, Glasgow
10:45	The gut microbiome: a new risk factor for obesity and CVD	Thomas F. Lüscher, London
11:05	Panel discussion
11:30 – 12:00 | COFFEE

12:00 – 12:30 | Keynote lecture
	Medical management of obesity: GLP-1/GIP agonists	John E. Deanfield, London

12:00 – 13:30 | Session 2: Obesity II – Management Chairs: Naveed Sattar & Thomas F. Lüscher
12:30	Behavioural management: Nutrition	Michael Lean, Glasgow
12:50	Bariatric surgery: is there still a role?	Ahmed R. Ahmed, London
13:10	Panel discussion
13:30 – 14:30  |  LUNCH BREAK

14:30 – 16:00 | Session 3: ASCVD Assessment I Chairs: Mahmoud Barbir & Thomas F. Lüscher
14:30	Cardiovascular risk assessment: the ESC SCORE/SCORE2-OP The ESC Guidelines	François Mach, Geneva
14:50	LDL-C and cardiovascular disease: Why is lower better?	Lale Tokgozolu, Ankara
15:10	Lifetime risk: CVD prevention – personal and national strategy	John E. Deanfield, London
15:30	Panel discussion
16:00 – 16:30 | COFFEE

16:30 – 17:30 | Case-based interactive seminars I
	How to assess adiposity: Clinical, MRI and beyond	Esmeralda Capristo, Rome
	How to manage obesity	Piya Sen Gupta, London
17:30 | End of day 1

DAY 2, Thursday, March 20th, 2025

09:00 – 10:30 | Session 4: ASCVD Assessment II & Management Chairs: Lale Tokgözoğlu & Riyaz Patel
09:00	Multimodality imaging to assess ASCVD	Rebecca Scholfield, Peterborough
09:20	Perivascular fat: Therapeutic target or surrogate of vascular disease?	Charalambos Antoniades, Oxford
09:40	siRNA for LDL-C and Lipoprotein(a)	Ulf Landmesser, Berlin
10:00	Remnant cholesterol and triglycerides in cardiovascular disease	Børge Nordestgaard, Copenhagen
10:20	Panel discussion
10:45 – 11:15 | COFFEE

11:15 – 12:15 | Live demonstrations
	Practical lipid apheresis	Mahmoud Barbir & Alison Pottle, London
	Pulse wave velocity and central blood pressure measurement – Practical demonstration	Christian Heiss, Guildford
12:15 – 13:00 | Industry Sponsored Symposium
	Lp(a) and its role in CV risk management: why, who, when & how to test?
13:00 – 13:45 | LUNCH BREAK and INTERACTIVE		INDUSTRY EXHIBITION

13:45 – 15:10 | Session 5: Diabetes mellitus (DM) Chairs: Eleanor Wicks & William Alazawi
13:45	Pathogenesis of type 2 DM	Janaka Karaliedde, London
14:05	Diabetes Type 2 and CVD beyond glucocentricity	Stephan Jacob, Villingen
14:25	Management of CVD risk in type 2 diabetes – the 2023 ESC Diabetes guidelines	Katharina Schütt, Aachen
14:45	Panel discussion

15:10 – 16:10 | Session 6: Nephrology – Chronic Kidney Disease (CKD) – Causes & Mechanisms   Chairs: Beatriz Fernadez-Fernandez & Raj Thakkar
15:10	CKD and cardiovascular risk	Parminder Judge, Oxford
15:30	Albuminuria, eGFR slopes and outcomes: impact of pharmacotherapy	David Wheeler, London
15:50	Panel discussion
16:10 – 16:30 | COFFEE

16:30 – 17:10 | Session 7: Nephrology – Chronic kidney disease (CKD) – Management  Chairs: Thomas Lüscher & Parminder Judge
16:30	SGLT2i and GLP1-RA in CKD and DKD – the 4 pillar approach	Beatriz Fernendez- Fernandez, Madrid
16:50	MR antagonists and CKD: effects and management of hyperkalaemia	Faiez Zannad, Nancy
17:10	Panel discussion

17:30 – 18:30  |  Case-based interactive seminars II
	Managing type 2 diabetes and CVD risk	Stephan Jacob, Villingen
	Managing patients with CKD	Beatriz Fernendez- Fernandez, Madrid
17:45 | End of day 2

DAY 3, Friday, March 21st, 2025

09:00 – 10:00 | Session 8: Metabolic dysfunction-associated steatotic liver disease (MASLD)  Chairs: Andrew Krentz & Geltrude Mingrone
09:00	Screening and diagnosis of MASLD	Philip Newsome, London
09:20	Management of MAFLD	William Alazawi, London
09:40	Panel discussion

10:00 – 11:00 | Session 9: Endocrinology and Cardiovascular disease  Chairs: NN & Nikhant Sabharwal
10:00	Cardiovascular risk in classic endocrine disease	Adrian Heald, Manchester
10:20	Sex hormones and CVD: Men vs Women	Andrew Krentz, London
10:40	Panel discussion
11:00 – 11:30 | COFFEE

11:30 – 12:30 | Session 10: Amyloid heart disease  Chairs: Eleanor Wicks & Nikant Sabharwal
11:30	The spectrum of amyloid heart disease	Ana Martinez Naharro, London
11:50	Diagnosis and management of cardiac amyloidosis	Marianna Fontana, London
12:10	Panel discussion
12:30 – 13:30 | LUNCH

13:30 – 15:00 | Session 11: Heart failure   Chairs: Eleanor Wicks & Shanti Velmurugan
13:30	Prevention of heart failure	Pardeep Jhund, Glasgow
13:50	Comorbidities of heart failure: obesity, diabetes and renal failure	Samuel Seidu, Leicester
14:10	Management of heart failure: the 2021 and 2023 ESC guidelines	Theresa McDonagh, London
14:30	Panel discussion
15:00 – 15:30 | COFFEE

16:00 – 17:00 | Case-based interactive seminars III
	Diagnosing MASLD with abdominal ultrasound	William Alazawi, London
	Diagnosing HFpEF, HFrEF and diabetic heart disease with echocardiography	Rajdeep Khattar, London
16:30 | End of day 3

---

General Information

Registration

Category
Registration fees
Early registration fee (until February 18th, 2025 )	GBP 400
Regular course fee	GBP 450
Early registration fee (until February 18th, 2025 ): Trainees/Residents, Research fellows, Nurses, Students <40 years (ID proof required)*	GPB 200
Trainees/Residents, Research fellows, Nurses, Students <40 years (ID proof required)*	GPB 250
Day Tickets	GPB 150

*For the reduced registration (Trainees/Residents, Research fellows, Nurses, Students <40 years) please send a copy of your ID to Ms. Christine Lohmann at christine.lohmann@zhh.ch

Registration will be confirmed upon receipt of payment.
Please note that UK banks may charge high fees for international bank transfers. We therefore recommend payment by credit card.

Travel Information

Travel to London

You must have a valid passport to enter the UK. It should be valid for the whole of your stay. You may also need a visa, depending on which country you’re from and the reason for your stay. Check if you need a visa to come to the UK. You must have your visa before you travel to the UK.

Electronic travel authorisation (ETA) 

From 2 April 2025, EU citizens will require an Electronic Travel Authorisation (ETA) to enter the UK. For non-EU citizens, the regulation will come into force on 8 January 2025. More information can be found on https://www.gov.uk/guidance/apply-for-an-electronic-travel-authorisation-eta. It will be possible to apply for the ETA, which will be required from April, from 5 March 2025 onwards. For nationals of certain countries outside Europe, the ETA will be required from 8 January 2025. The application is again possible from 27 November 2024: https://www.gov.uk/guidance/check-when-you-can-get-an-electronic-travel-authorisation-eta. You won’t have to apply in case you have a VISA.

Modification & Cancellation

All modifications or cancellations must be notified in writing (by mail, fax or e-mail) to Zurich Heart House. For each modification requested by the participant, GBP 15 will be charged for administrative costs. In case of cancellation up to March 1st, 2025, deposits will be refunded less 35% for administrative costs. After this date, no refund will be possible.

Venue

The Royal Society of Medicine,
1 Wimpole St, Marylebone, London W1G 0AE, United Kingdom

Organisation

Zurich Heart House, / London Heart House, Foundation for Cardiovascular Research
Eleanor Wicks
Christine Lohmann
Hottingerstrasse 14, CH-8032 Zurich, Switzerland
Phone +41 (0) 44 250 40 95 
www.zhh.ch / www.londonhearthouse.uk 

---

Accreditation

The Postgraduate Course in Cardiometabolic Medicine has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 18 category 1 (external) CPD credit(s)

The Postgraduate Course in Cardiometabolic Medicine has been accredited 
by the European Accreditation Council for Continuing Medical Education (EACCME®)
for a maximum of 18.0 European CME credits (ECMEC®s)

---

Teaching Faculty

---

Sponsors

Under the Auspices of

---

In collaboration with

---

---

Register here